Paediatric use of melatonin (Author reply to D. J. Kennaway)

      We thank Prof. David Kennaway for his remarks regarding the safety of melatonin and the timing of its administration, which gives us the opportunity of clarifying these important issues.
      • Kennaway D.J.
      Paediatric use of melatonin.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Paediatric Neurology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kennaway D.J.
        Paediatric use of melatonin.
        Eur J Paediatr Neurol. 2015;
        • Bruni O.
        • Alonso-Alconada D.
        • Besag F.
        • Biran V.
        • Braam W.
        • Cortese S.
        • Moavero R.
        • Parisi P.
        • Smits M.
        • Van der Heijden K.
        • Curatolo P.
        Current role of melatonin in pediatric neurology: clinical recommendations.
        Eur J Paediatr Neurol. 2015; 19: 122-133
        • Hartz I.
        • Furu K.
        • Bratlid T.
        • Handal M.
        • Skurtveit S.
        Hypnotic drug use among 0-17 year olds during 2004-2011: a nationwide prescription database study.
        Scand J Pub Health. 2012; 40: 704-707
      1. Kryger M.H. Roth T. Dement W.C. Principles and practice of sleep medicine. 5th ed. WB Saunders, St Louis2011
        • Hoebert M.
        • van der Heijden K.B.
        • van Geijlswijk I.M.
        • Smits M.G.
        Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia.
        J Pineal Res. 2009; 47: 1-7
        • van Geijlswijk I.M.
        • Korzilius H.P.
        • Smits M.G.
        The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis.
        Sleep. 2010; 33: 1605-1614
        • van Geijlswijk I.M.
        • Mol R.H.
        • Egberts T.C.
        • Smits M.G.
        Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia.
        Psychopharmacology. 2011; 216: 111-120
        • Carr R.
        • Wasdell M.B.
        • Hamilton D.
        • Weiss M.D.
        • Freeman R.D.
        • Tai J.
        • Rietveld W.J.
        • Jan J.E.
        Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders.
        J Pineal Res. 2007; 43: 351-359
        • Appleton R.E.
        • Jones A.P.
        • Gamble C.
        • Williamson P.R.
        • Wiggs L.
        • Montgomery P.
        • Sutcliffe A.
        • Barker C.
        • Gringras P.
        The use of melatonin in children with neurodevelopmental disorders and impaired sleep: a randomized, double-blind, placebo-controlled, parallel study (MENDS).
        Health Technol Assess. 2012; 16: i-239
        • Biran V.
        • PhanDuy A.
        • Decobert F.
        • Bednarek N.
        • Alberti C.
        • Baud O.
        Is melatonin ready to be used in preterm infants as a neuroprotectant?.
        Dev Med Child Neurol. 2014; 56: 717-723
        • Luboshitzky R.
        • Lavi S.
        • Thuma I.
        • Lavie P.
        Increased nocturnal melatonin secretion in male patients with hypogonadotropic hypogonadism and delayed puberty.
        J Clin Endocrinol Metab. 1995; 80: 2144-2148
        • Mauriz J.L.
        • Collado P.S.
        • Veneroso C.
        • Reiter R.J.
        • González-Gallego J.
        A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives.
        J Pineal Res. 2013; 54: 1-14
        • Chen J.
        • Chen G.
        • Li J.
        • Qian C.
        • Mo H.
        • Gu C.
        • Yan F.
        • Yan W.
        • Wang L.
        Melatonin attenuates inflammatory response-induced brain edema in early brain injury following a subarachnoid hemorrhage: a possible role for the regulation of pro-inflammatory cytokines.
        J Pineal Res. 2014; 57: 340-347
        • EFSA. Panel on Dietetic Products, Nutrition and Allergies (NDA)
        Scientific opinion on the substantiation of health claims related to melatonin and alleviation of subjective feelings of jet lag (ID 1953), and reduction of sleep onset latency, and improvement of sleep quality (ID 1953) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.
        EFSA J. 2010; 8 ([14 pp.]): 1467
        • EFSA. Panel on Dietetic Products, Nutrition and Allergies (NDA)
        Scientific opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.
        EFSA J. 2011; 9 ([16 pp.]): 2241
        • Braam W.
        • Didden R.
        • Smits M.G.
        • Curfs L.M.
        Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study.
        J Intellect Disabil Res. 2008; 52: 256-264
        • van Maanen A.
        • Meijer A.M.
        • Smits M.G.
        • Oort F.J.
        Termination of short term melatonin treatment in children with delayed dim light melatonin onset: effects on sleep, health, behavior problems, and parenting stress.
        Sleep Med. 2011; 12: 875-879
        • Keijzer H.
        • Smits M.G.
        • Duffy J.F.
        • Curfs L.M.
        Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders.
        Sleep Med Rev. 2014; 18: 333-339